Clinical trials located in

Thessaloniki

Thessaloniki city is located in Greece. Currently, 20 clinical trials are being conducted in this city.

Thessaloniki, Greece’s second-largest city, boasts a rich history dating back over 2,300 years. Founded in 315 BC by King Cassander, it was named after his wife, Thessalonike, sister of Alexander the Great. This cosmopolitan city is renowned for its vibrant festivals, cultural events, and historic landmarks, including the iconic White Tower and the UNESCO-listed Byzantine walls. Thessaloniki’s culinary scene reflects its diverse history, offering a blend of Greek, Balkan, and Mediterranean flavors. The city also serves as a gateway to exploring the stunning landscapes of Northern Greece.

  • CT-EU-00121729

    Safety and efficacy study of BA3021 for patients with lung cancer, breast cancer, melanoma, or head and neck cancer

    This clinical trial targets various types of cancer such as Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Melanoma, and Head and Neck Cancer. The therapy being assessed involves BA3021 (CAB-ROR2-ADC), a specialized drug designed to target cancer cells. Another drug, a PD-1 inhibitor, will also be used in one part of the study.

    The primary goal of this study is to evaluate the safety and effectiveness of BA3021, alone or in combination with a PD-1 inhibitor, in treating advanced solid tumors.

    This trial will be carried out in two phases:
    Phase 1 will focus on understanding the appropriate dose and its safety, while
    Phase 2 will evaluate how well the drug works alone or together with the PD-1 inhibitor.

    Participants will receive either BA3021 alone or BA3021 in combination with the PD-1 inhibitor. They will be monitored closely throughout the study to track their health and the drug’s effects on their cancer.

  • Study of Giredestrant and other drugs in patients with HER2-negative early breast cancer

    This study focuses on early stage breast cancer with estrogen receptor (ER)-positive and HER2-negative status. The study compares the effectiveness and safety of giredestrant with the physician’s choice of endocrine (hormonal) therapy.

    The study involves participants with histologically confirmed (histology is the study of tissues) early stage breast cancer in stages I to III, who are at medium to high risk. Patients must have had their primary breast tumor and axillary lymph nodes surgically removed.

    The aim is to evaluate how well giredestrant works compared to the standard hormonal therapy chosen by the physician in preventing the recurrence of cancer after treatment for early stage breast cancer. Giredestrant is administered orally once daily for 5 years.

    Both men and women may qualify for the study, provided they meet certain health and surgical criteria. This study also includes an additional substudy to explore the safety of combining giredestrant with abemaciclib in a selected group of participants.

    Giredestrant acts as an antagonist (blocking agent) to estrogen receptors, aiming to reduce the risk of cancer recurrence. Abemaciclib is an oral medication that inhibits the enzyme called cyclin-dependent kinase 4/6 (CDK4/6), which helps to stop the growth of cancer cells.

    The ultimate goal of the study is to determine whether giredestrant or its combination with abemaciclib can offer better treatment outcomes than the currently used hormonal therapies in preventing breast cancer recurrences.

    • Endocrine Therapy of Physician’s Choice
    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
  • Study of Apremilast in the treatment of oral ulcers in children with Behçet’s syndrome or juvenile arthritis associated with psoriasis

    This study is investigating a drug called Apremilast, which comes as oral tablets or a liquid suspension. The main aim of this study is to investigate the long-term safety of apremilast in children and young people suffering from two different diseases: Juvenile psoriatic arthritis and Behçet’s disease.

    For young children aged 2 years or older, researchers will test whether Apremilast is safe to treat mouth ulcers related to a condition called Behçet’s disease. However, in older children from 5 years of age, it will be checked whether Apremilast is safe in the treatment of active juvenile psoriatic arthritis.

    This study is called a “long-term extension” study. This means that participants have already completed one of two previous studies of apremilast and are now invited to continue taking the drug for another 4 years. During this time, researchers will closely monitor any adverse events and side effects that participants may experience.

    They will also monitor other important health indicators such as changes in weight, height, body mass index, vital signs such as blood pressure and heart rate, as well as any significant changes in routine laboratory tests of blood and urine samples.

    The aim of this study is to collect key long-term safety data on the use of apremilast in the treatment of oral ulcers in Behçet’s disease and juvenile psoriatic arthritis in children and young adults. Scientists want to make sure the drug will be safe for long-term use in young patients before it can be approved to treat these conditions.

    • Apremilast
  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Safety and efficacy of pembrolizumab in combination with investigational drugs in the first-line treatment of patients with melanoma

    The aim of this study is to test new experimental treatments for melanoma, which is a type of skin cancer. The main goal is to test whether these new treatments are safe and effective when used alone or in combination with the drug pembrolizumab.

    The current study includes several different treatment groups. Some groups receive pembrolizumab in combination with other investigational drugs such as vibostolimab, quavonlimab, lenvatinib, favezelimab, or Tretynoina (ATRA). Other groups simply receive pembrolizumab alone.

    Scientists will carefully look at factors such as dose-limiting toxicities and adverse events to make sure the treatment is safe. They will also check the effectiveness of the therapy by measuring, for example, the objective response rate, which shows whether tumors are shrinking or disappearing.

    • Tretynoina
    • Vibostolimab
    • Quavonlimab
    • Favezelimab
    • Pembrolizumab
    • Lenvatinib
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Exploring Fipaxalparant as a new treatment method for Diffuse Cutaneous Systemic Sclerosis

    This extensive study, conducted across multiple hospitals, aims to assess the effectiveness and safety of a Fipaxalparant (HZN-825), in individuals with a skin condition known as Diffuse Cutaneous Systemic Sclerosis. The study employs a double-blind design, where some participants receive the actual drug, and others receive a placebo (a drug with no active substance), with neither the doctors nor the patients being aware of which treatment they are receiving. The trial is scheduled to run for approximately one year, with regular check-ups every six weeks. If participants successfully complete the year-long trial, they may be invited to continue using the drug for an additional year in a follow-up study. For safety reasons, a check-up will also be conducted four weeks after participants stop taking the drug.

    • Fipaxalparant/HZN-825
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Examining new drug impact on nonalcoholic fatty liver disease

    This study is evaluating GSK4532990 in adults with advanced non-alcoholic steatohepatitis (NASH). This is a Phase 2b trial comparing GSK4532990 with placebo, focusing on liver fibrosis and inflammation relief. The study will include high-dose, low-dose and placebo groups and will include 246 participants. Primary outcomes are improvement in histologic fibrosis and resolution of NASH at 52 weeks. Secondary outcomes include changes in liver and fat markers.

    • GSK4532990- new potential medication for fatty liver disease
  • Examining repotrectinib vs crizotinib in advanced lung cancer treatment

    This trial is named TRIDENT-3, it’s for people who have a particular type of lung cancer that has spread beyond the lungs (advanced or metastatic). The lung cancer for this study is called ‘Non-Small Cell Lung Cancer’ (NSCLC) and it’s positive for an important part of the cells called ‘ROS1.’ The trial will compare two medicines: repotrectinib and crizotinib. People participating in the trial have not been treated with a group of drugs called ‘Tyrosine Kinase Inhibitors’ (TKIs) before. The main goal of this study is to see how effective and safe these two drugs are for these patients.

    • Repotrectinib
    • Crizotinib
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Iptacopan’s effect on adult patients with atypical hemolytic uremic syndrome

    This study is conducted to understand if a medicine called iptacopan (also known as LNP023) is safe and effective in treating a disease called Atypical Hemolytic Uremic Syndrome (aHUS) in adults who have never received a type of medication known as a complement inhibitor. Around 50 adults will be given 200 mg of this iptacopan pill twice a day. The doctors will measure how their illness responds by looking at blood tests, kidney health, how often they need to have their blood cleansed by a machine (dialysis), the progression of their kidney illness, and how they feel energetically and about their quality of life. Side effects of taking iptacopan will be recorded for a year.

    • Iptacopan
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Comparing sotorasib and pembrolizumab in treating advanced nonsquamous non-small cell lung cancer

    This trial is testing two first-line therapies in people with advanced lung cancer. Two drugs, Sotorasib and Pembrolizumab, are compared, each combined with a special type of chemotherapy known as a “platinum doublet.” The goal is to determine which combination of these two treatments works most effectively in slowing the growth of the cancer or extending the patient’s life. Patients are selected based on the type and stage of lung cancer. The trial is considered appropriate for people with advanced stage IIIB, IIIC or IV non-squamous non-small cell lung cancer. Additionally, the test is intended for people whose cancer cells show a specific response, including no response to PD-L1, but a positive response to KRAS p. G12C.

    • Sotorasib
    • Pembrolizumab
  • Evaluation of Bemarituzumab in patients with solid tumors overexpressing the FGFR2b receptor

    The study concerns patients with solid tumors that are characterized by excessive expression of the FGFR2b receptor (Fibroblast Growth Factor Receptor 2b). In particular, this includes cancers such as head and neck squamous cell carcinoma, triple negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma and cervical cancer. The therapy that will be used in this study is bemarituzumab (also known as AMG 552), administered by intravenous infusion.

    The aim of the study is to assess the safety and tolerability of bemarituzumab and its preliminary anticancer effectiveness. Patients with the above cancers whose disease recurs or does not respond to standard therapies may be eligible to participate in the study.

    Patients must have confirmed recurrent or refractory cancer that is not suitable for surgical treatment. An additional condition is excessive expression of the FGFR2b receptor in their tumor. The experimental therapy includes two phases: in the first phase, determining the optimal dose, and in the second, expanding the therapy to a larger group of patients using a previously determined dose.

    • Bemarituzumab
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    • Datopotamab deruxtecan
    • Pembrolizumab

See more clinical trials in other cities in Greece:

.